Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Articles

The future is set to be a running theme for this year’s CPHI event, which will take place in-person at the Fira Barcelona Gran Via in Spain between 24–26 October 2023.

Planning the Future of Pharma at CPHI

Here is a small selection of some of the inspiring places to visit while in Barcelona, Spain.

Bright Lights, Big City: Touring Barcelona

Through the acquisition, Avacta gains Coris’ product portfolio consisting of diagnostic tests for respiratory, gastroenteric, and blood-borne pathogens as well as for the detection of antibiotic resistance markers.

Avacta Acquires Coris BioConcept to Grow Diagnostics Product Portfolio

Feliza Mirasol is the science editor for 

WuXi Biologics is expanding its manufacturing capacity for drug substance and drug product at its sites in Leverkusen and Wuppertal, Germany.

WuXi Biologics Expands Manufacturing Capacity in Germany

A partnership between Rentschler Biopharma and Ikarovec will support the accelerated development of novel gene therapies for the treatment of eye diseases.

Rentschler Biopharma, Ikarovec Collaboration Set to Speed Up Ophthalmic Therapy Development 

The start of production of US engineering batches of NXC-201, a CAR-T cell therapy candidate in early clinical development, is the first step in transferring Nexcella’s existing manufacturing process to the United States.

Nexcella Begins Production of CAR-T Cell Therapy Engineering Batches at US Manufacturing Site

API supplier Olon has started construction of a new manufacturing facility in Milan, Italy, which will be dedicated to production of cytotoxic payloads and linkers for ADCs.

Olon Makes Headway into ADCs Market with New Manufacturing Facility in Italy

Sandoz’s marketing authorization applications for a proposed biosimilar to denosumab are supported by a comprehensive analytical and clinical data package.

EMA Accepts MAAs from Sandoz for Proposed Denosumab Biosimilar

Under the new MTA and Option License Agreement, Adcendo can nominate ADCs against two novel ADC targets, according to the press release.

Adcendo and Duality Biologics in License Agreement to Expand ADC Pipeline

The project is being coordinated by the recently formed not-for-profit CCRM Nordic AB and gathers engaged stakeholders to move the initiative forward.

News